| For: | Xie XZ, Zuo L, Huang W, Fan QM, Weng YY, Yao WD, Jiang JL, Jin JQ. FDX1 as a novel biomarker and treatment target for stomach adenocarcinoma. World J Gastrointest Surg 2024; 16(6): 1803-1824 [PMID: 38983344 DOI: 10.4240/wjgs.v16.i6.1803] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9366/full/v16/i6/1803.htm |
| Number | Citing Articles |
| 1 |
Long Qin, ZhenBing Lv, BinYu Luo, Jing Yu, Min Li, Rong Jing, JingDong Li. Hypoxia-induced autophagy attenuates ferredoxin 1-mediated cuproptosis in colorectal cancer cells. Human & Experimental Toxicology 2025; 44 doi: 10.1177/09603271251335393
|
| 2 |
Zhe Chen, Jin Zhao, Na Xiao, Fu’e Zhang, Shujian Zhao, Hongshan Yin. Identification of biomarkers associated with SUMO modification in heart failure. Medicine 2025; 104(42): e44982 doi: 10.1097/MD.0000000000044982
|
| 3 |
Yixian Li, Wenhao Sun, Shaolin Yuan, Xinxin Liu, Ziqi Zhang, Renjun Gu, Pengfei Li, Xin Gu. The role of cuproptosis in gastric cancer. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1435651
|
| 4 |
Jing Peng, Qi Yan, Wennan Pei, Yi Jiang, Li Zhou, Ruoqing Li, Minghua Ren. A Prognostic Riskscore Model Related to Helicobacter pylori Infection in Stomach Adenocarcinoma. International Journal of Genomics 2025; 2025(1) doi: 10.1155/ijog/5554610
|
| 5 |
Annan Wu, Kai Tu, Guangfeng Xia. The emerging role of ferredoxin 1 in cancer: Insights into cuproptosis and therapeutic innovation. International Journal of Biological Macromolecules 2025; 330: 147996 doi: 10.1016/j.ijbiomac.2025.147996
|
| 6 |
Ling Lu, Wenhui Yang, Yuning Gu, Longtao Jin, Zhaofeng Liang. The role of cuproptosis in the occurrence and development of gastric cancer. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1664200
|
